Followers | 294 |
Posts | 9254 |
Boards Moderated | 2 |
Alias Born | 04/22/2005 |
Friday, February 04, 2022 7:22:11 AM
Covered call strategy. My Jan 4.00 calls expired worthless effectively lowering the cost of my shares .40 from 2.65 to 2.25 cost basis. I’m hoping FDA approval moves the stock well. With earnings approaching coupled with FDA expectations, option prices will be highly overvalued which makes writing them very profitable with increased chances of making winning trades. I hope to be free riding all my original shares by the end of 2022 with this “hands off my shares”approach.
LEAPS
Covered half my wrote 2023 10 calls (sold at 1.30) at .40 and hope to buy back the rest today around .45. If so I will effectively lower the cost of my Jan 2023 2.00 calls to .72 from 1.60. Hoping to free ride them by writing short term calls against against them.
Also looking at purchasing Jan 2024 2.50c at 1.60
Recent SENS News
- Senseonics Holdings, Inc. to Participate in Upcoming Conferences • Business Wire • 05/02/2024 12:05:00 PM
- Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time • Business Wire • 04/30/2024 08:05:00 PM
- Eversense® CGM System Receives iCGM Designation by the US FDA • Business Wire • 04/30/2024 11:00:00 AM
- SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS • PR Newswire (US) • 03/12/2024 11:00:00 AM
- Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes • Business Wire • 03/08/2024 01:05:00 PM
- Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference • Business Wire • 03/06/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:12:59 PM
- Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/29/2024 09:05:00 PM
- Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time • Business Wire • 02/15/2024 09:05:00 PM
- Medicare Coverage Significantly Expanded for the Eversense E3 CGM System • Business Wire • 02/12/2024 12:00:00 PM
- MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM • PR Newswire (US) • 02/12/2024 12:00:00 PM
- PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care • Business Wire • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:49:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:48:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:47:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:36:51 PM
- Senseonics Holdings, Inc. Announces Business Updates • Business Wire • 01/02/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:57:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:56:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:54:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:53:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:27:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:14:22 PM
- Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM